Volume 59, Issue 3, Pages (September 2013)

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
Evangelos Cholongitas, George V. Papatheodoridis, Andrew K. Burroughs 
Volume 65, Issue 1, Pages S82-S94 (October 2016)
Inflammasomes in liver diseases
Volume 61, Issue 4, Pages (October 2014)
Volume 67, Issue 3, Pages (September 2017)
Volume 50, Issue 4, Pages (April 2009)
Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges  Marie-Louise Michel, Qiang Deng,
Geoffrey W McCaughan, Amany Zekry  Journal of Hepatology 
Hepatic CD141+IFNλ+ DC subset: One against all?
The yin and yang of evasion and immune activation in HCC
Volume 42, Issue 6, Pages (June 2005)
Reactive oxygen species in the normal and acutely injured liver
Obesity, inflammation, and liver cancer
Geoffrey W McCaughan, Amany Zekry  Journal of Hepatology 
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Liver regeneration Journal of Hepatology
NS5A inhibitors in the treatment of hepatitis C
Hedgehog signaling in the liver
Volume 65, Issue 1, Pages S82-S94 (October 2016)
Immigration and viral hepatitis
Mast cell–T cell interactions
Regulatory T-cell directed therapies in liver diseases
Allogeneic hematopoietic cell transplant in HCV-infected patients
Living donor liver transplantation: is the hype over?
Nicolas Moniaux, Jamila Faivre  Journal of Hepatology 
Gut–liver immunity Journal of Hepatology
David G. Bowen, Christopher M. Walker  Journal of Hepatology 
Volume 69, Issue 2, Pages (August 2018)
Volume 44, Pages S19-S24 (January 2006)
Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection  Anaïs Vallet-Pichard,
Inflammation and portal hypertension – The undiscovered country
Evangelos Cholongitas, George V. Papatheodoridis, Andrew K. Burroughs 
Chronic HCV infection and the clonality of intrahepatic T cells
From immunosuppression to tolerance
Hepatitis C and Lymphoproliferative Disorders: From Mixed Cryoglobulinemia to Non- Hodgkin's Lymphoma  Lenna A. Martyak, Melina Yeganeh, Sammy Saab  Clinical.
Regulatory T-cell directed therapies in liver diseases
Hepatitis C core protein – The “core” of immune deception?
Signalling pathways in alcohol-induced liver inflammation
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges  Marie-Louise Michel, Qiang Deng,
Hepatocyte-like cells differentiated from human induced pluripotent stem cells (iHLCs) are permissive to hepatitis C virus (HCV) infection: HCV study.
I. Carmona, P. Cordero, J. Ampuero, A. Rojas, M. Romero-Gómez 
Targets for immunotherapy of liver cancer
The yin and yang of evasion and immune activation in HCC
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Volume 45, Issue 4, Pages (October 2006)
Volume 62, Issue 3, Pages (March 2015)
Liver is liver and blood is blood, and finally the twain have met
Autophagy in the liver Journal of Hepatology
Volume 59, Issue 3, Pages (September 2013)
Veronika Lukacs-Kornek, Detlef Schuppan  Journal of Hepatology 
Volume 42, Issue 3, Pages (March 2005)
Cannabinoid signaling and liver therapeutics
Volume 50, Issue 4, Pages (April 2009)
Arjan Boltjes, Dowty Movita, André Boonstra, Andrea M. Woltman 
Immigration and viral hepatitis
The potential of induced pluripotent stem cell derived hepatocytes
Role of desmoplasia in cholangiocarcinoma and hepatocellular carcinoma
Volume 63, Issue 1, Pages (July 2015)
Macrophage heterogeneity in liver injury and fibrosis
Silvia Affò, Ramón Bataller  Journal of Hepatology 
Volume 62, Issue 6, Pages (June 2015)
Liver transplantation in children
Pathogenesis of cholestatic hepatitis C
Chimeric mouse model of hepatitis B virus infection
Eric Robinet, Thomas F. Baumert  Journal of Hepatology 
Platelets arrive at the scene of fibrosis……studies
Presentation transcript:

Volume 59, Issue 3, Pages 613-615 (September 2013) Blockade of CCR5 to protect the liver graft in HIV/HCV co-infected patients  Stéphanie Haïm-Boukobza, Karl Balabanian, Elina Teicher, Marion Bourgeade, Gabriel Perlemuter, Anne-Marie Roque-Afonso, Jean- Charles Duclos-Vallee  Journal of Hepatology  Volume 59, Issue 3, Pages 613-615 (September 2013) DOI: 10.1016/j.jhep.2013.03.034 Copyright © 2013 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Expected effects of the CCR5 antagonist maraviroc. (1) On liver fibrosis: hepatitis C virus (HCV) infection induces inflammation and liver injury, leading to the activation of Kupffer cells and the production of chemokines and cytokines. TGF-β synthesis activates hepatic stellate cells (HSC), inducing liver fibrosis through collagen production. Fibrosis and inflammation due to HCV infection increase the CCR5 expression of cell types involved in fibrosis. The HIV infection of HSC increases the transformation of HSC into myofibroblasts. Through its envelope glycoprotein, the human immunodeficiency virus (HIV) can increase TGF-β synthesis, which in turn leads to increased HSC activation and HCV replication. HCV enhances the production of chemokines such as CCL5 by endothelial cells, which in turn attracts CD8 T-cell lymphocytes (CTL) into the liver graft. These specific CTL produce CCL5. →Maraviroc could be used to reduce liver fibrosis. (2) On HIV infection: the CCR5 antagonist maraviroc inhibits the entry of R5 tropic HIV variants into monocytes or activated CD4 T-lymphocytes. (3) On liver graft rejection: T-cells in the recipient recognize allogeneic major histocompatibility complex (MHC) molecules on the surface of donor Kuppfer cells, leading to CCL3, CCL4, and CCL5 production and CTL recruitment into the liver graft. →Maraviroc could be used to decrease the recruitment of CTL and hence inhibit graft rejection. Journal of Hepatology 2013 59, 613-615DOI: (10.1016/j.jhep.2013.03.034) Copyright © 2013 European Association for the Study of the Liver Terms and Conditions